VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

S. agalactiae BipA Protein Vaccine S. agalactiae BPS Protein Vaccine S. agalactiae Rib Protein Vaccine S. agalactiae Sip Protein Vaccine
Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004200
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant BipA protein
  • BipA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
    • VO ID: VO_0000139
    • Description: Complete Freund's adjuvant on day 1, incomplete Freund's adjuvant on day 35 (Santi et al., 2009).
  • Adjuvant: incomplete Freunds adjuvant
    • VO ID: VO_0000142
    • Description: Complete Freund's adjuvant on day 1, incomplete Freund's adjuvant on day 35 (Santi et al., 2009).
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0004050
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant BPS
  • sar5 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: aluminum phosphate vaccine adjuvant
    • VO ID: VO_0000128
    • Description: Aluminum phosphate (Adju-Phos; Axell Accurate Chemical & Scientific Corp.) (Erdogan et al., 2002).
  • Immunization Route: subcutaneous injection
  • Vaccine Ontology ID: VO_0004051
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Purified Rib protein
  • rib gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
    • VO ID: VO_0000139
    • Description: 0.1 ml of complete Freund’s adjuvant.
  • Immunization Route: subcutaneous injection
  • Vaccine Ontology ID: VO_0004052
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant Sip protein.
  • Sip gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: QuilA vaccine adjuvant
  • Immunization Route: subcutaneous injection
Host Response Host Response Host Response Host Response

Mouse Response

  • Host Strain: CD‐1
  • Vaccination Protocol: Active mouse maternal immunization.A maternal immunization/neonatal pup challenge model of GBS infection was used to verify the protective efficacy of BibA protein in mice. CD‐1 female mice (6–8 weeks old) were immunized intraperitoneally on days 1 (complete Freund’s adjuvant), 21, and 35 (incomplete Freund’s adjuvant) with either PBS or 20 μg of recombinant protein and were then bred 3 days after the last immunization (Santi et al., 2009).
  • Challenge Protocol: Within 48 h of birth, pups were injected intraperitoneally with a dose of GBS strain 3050 that would be lethal to 90% of the population, corresponding to 3 x 104 colony‐forming units (CFU). Survival of pups was monitored for 3 days after challenge (Santi et al., 2009).
  • Efficacy: Immunization of mice with recombinant BibA conferred protection to 69% of the challenged pups (Santi et al., 2009).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Four-week-old female BALB/c (H-2d) mice were immunized with recombinant BPS protein on days 1, 3, 6, and 27 (30 μg/dose) by the subcutaneous route with aluminum phosphate as the adjuvant (Erdogan et al., 2002).
  • Challenge Protocol: Groups of immunized and control animals were challenged on day 37 with an inoculum of the streptococcal strain Compton R corresponding to the 80% lethal dose (LD80; 5 × 108 bacteria/ml) in nonimmunized mice, and mortality was recorded daily (Erdogan et al., 2002).
  • Efficacy: When the immunized animals were challenged with strain Compton R, approximately 88% of the vaccinated animals survived whereas mice in the control group were not protected (78% lethality) (Erdogan et al., 2002).

Mouse Response

  • Host Strain: C3H/HeN
  • Vaccination Protocol: Male C3H/HeN mice, 7 to 13 weeks old, were immunized subcutaneously with 25 μg of pure protein (Rib or bovine serum albumin [BSA]) in 0.1 ml of phosphate-buffered saline (PBS) mixed with 0.1 ml of complete Freund’s adjuvant. Four weeks later the mice were given boosters of the same amount of protein with incomplete Freund’s adjuvant (Larsson et al., 1996).
  • Challenge Protocol: Two weeks after the booster, the mice were injected intraperitoneally (i.p.) with a 90% lethal dose (LD90) of log-phase bacteria, diluted in 0.5 ml of Todd-Hewitt broth. The LD90 for the different strains varied between 106 and 107 bacteria, as determined in preliminary experiments (Larsson et al., 1996).
  • Efficacy: Vaccination of mice with the Rib protein protected against two strains of capsular type III and two strains of type II (Larsson et al., 1996).

Mouse Response

  • Host Strain: CD-1
  • Vaccination Protocol: Mice were injected s.c. three times at 3-week intervals with either 20 μg of purified recombinant Sip protein in 0.1 ml of PBS mixed with 20 μg of QuilA adjuvant (Cedarlane), 15 μg of formaldehyde-killed GBS WC with 20 μg of QuilA as positive controls, or 20 μg of QuilA in PBS as a negative control (Brodeur et al., 2000).
  • Challenge Protocol: To evaluate the challenge dose required for each GBS strain, between 104 and 108 CFU/mouse was injected i.p. into groups of CD-1 female mice (Brodeur et al., 2000).
  • Efficacy: Immunization with the recombinant Sip protein efficiently protected CD-1 mice against deadly challenges with six GBS strains of serotypes Ia/c, Ib, II/R, III, V, and VI (Brodeur et al., 2000).
References References References References
Santi et al., 2009: Santi I, Maione D, Galeotti CL, Grandi G, Telford JL, Soriani M. BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. The Journal of infectious diseases. 2009; 200(4); 564-570. [PubMed: 19586417].
Erdogan et al., 2002: Erdogan S, Fagan PK, Talay SR, Rohde M, Ferrieri P, Flores AE, Guzmán CA, Walker MJ, Chhatwal GS. Molecular analysis of group B protective surface protein, a new cell surface protective antigen of group B streptococci. Infection and immunity. 2002; 70(2); 803-811. [PubMed: 11796614].
Larsson et al., 1996: Larsson C, Stålhammar-Carlemalm M, Lindahl G. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Infection and immunity. 1996; 64(9); 3518-3523. [PubMed: 8751893].
Brodeur et al., 2000: Brodeur BR, Boyer M, Charlebois I, Hamel J, Couture F, Rioux CR, Martin D. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infection and immunity. 2000; 68(10); 5610-5618. [PubMed: 10992461].